HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIRB), the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear®, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe. Xerclear® will be marketed under the trade name Zoviduo and Zovirax Duo in Europe.
